Table 5.
Selected private biotech companies with a business interest in prophylactic vaccine development
| Company (location) | Prophylactic vaccine focus (development phase, if any) | Technology | Business strategy |
|---|---|---|---|
| Antigenics (New York) | Genital herpes (phase 1/2) | Antigen from herpes simplex virus type 2 vaccine complexed with heat-shock protein | Developing immunotherapies for cancer, infectious diseases, autoimmune degenerative disorders. Partnered with GlaxoSmithKline, Wyeth, Aventis Pasteur, Progenics, Elan |
| http://www.antigenics.com/ | |||
| Aridis Pharmaceuticals (Sunnyvale, CA, USA) | Shigella and rotavirus | Dehydration technology and addition of stabilizers that enhance vaccine half-life | Developing new vaccine formulations, processing and delivery approaches. Partnered with the NIH |
| AuRx (Glen Burnie, MD, USA) | Genital herpes (phase 1) | Herpes simplex virus type 2 vaccine attenuated by recombinant technology. | Focused on vaccines and therapies for herpes simplex type 2 |
| http://www.aurx.com/index.htm | |||
| Avecia Biotechnology (Manchester, UK) | Plague and anthrax | Oligonucleotide synthesis and biologic manufacture | Contract manufacturing services for DNA and protein vaccines |
| http://www.avecia.com/biotech/default.htm | |||
| Bharat Biotech (Hyderabad, India) | Hepatitis B (launched) and typhoid (launched) | Recombinant hepatitis B virus surface antigen vaccine and purified Salmonella typhi Vi capsular polysaccharide | Vaccines, biopharmaceuticals and biomanufacturing. Partnered with Mvelaphanda (S. African gold and diamond company) |
| http://www.bharatbiotech.com/ | |||
| BioVirus Research (Reno, NV, USA) | Genital herpes | A computational platform for designing synthetic peptide vaccines | Focused on vaccines and therapies for herpes simplex virus type 2. Partnered with Tekron (Ft. Lauderdale, FL) |
| Cerus (Concord, CA, USA) | Anthrax | Expression of antigens on killed but metabolically active strains of Listeria monocytogenes | Vaccines and blood safety products for infectious disease and cancer. Partnered with MedImmune, Baxter Healthcare, BioOne |
| http://www.cerus.com | |||
| Emergent Biosolutions (Gaithersburg, MD, USA) | Anthrax, Chlamydia trachomatis, Helicobacter pylori and influenza | Aluminum hydroxide–adsorbed cell-free vaccine prepared from Bacillus anthracis strain V770-NP1-R | Vaccines and related products. BioPort manufacturing arm Antex Biologics, research arm acquired UK-based Microscience 2005. Expanded manufacturing capacity in 2004 with purchase of new facility in Frederick, Maryland |
| http://www.ebsi.com/home.asp | |||
| Epivax (Providence, RI, USA) | Helicobacter pylori ulcers, tularemia and smallpox | A computational platform for identifying T-cell epitopes in peptide sequences | Research services for vaccine development |
| http://epivax.com/ | |||
| GenPhar (Mt. Pleasant, SC, USA) | HIV (phase 1/2) | Adenovirus vectors for antigen delivery | Viral diagnostics, vaccines, cancer therapies. Partnered with NIH for testing HIV vaccine in monkeys and USAMIRD for Marburg |
| http://www.genphar.com/ | |||
| Hawaii Biotech (Aiea, HI, USA) | Influenza, West Nile virus, and dengue fever | Recombinant protein vaccines | Vaccines and small molecules. Partnered with Cobra for manufacture of dengue and West Nile vaccine |
| http://www.hibiotech.com | |||
| Novavax (Malvern, PA, USA) | HIV, influenza, hepatitis E and SARS | Expression in insect cells of virus-like particle technology for expressing antigens | Vaccines, drug delivery and biologics. Partnered with National Institute of Allergy and Infectious Diseases (NIAID), Walter Reed Army Institute for Research and GlaxoSmithKline |
| http://www.novavax.com | |||
| Oxxon Therapeutics (Oxford, UK) | Malaria (phase 2), tuberculosis (phase 1) and HIV (phase 2) | Prime-boost vaccines based on recombinant modified vaccinia virus, Ankara-expressing antigens | Vaccines and other immunotherapies for infectious disease and cancer. Partnered with Wellcome Trust, Medical Research Council and Malaria Vaccine Initiative |
| http://www.oxti.com | |||
| PowderMed (Oxford, UK) | Influenza (phase 1), HIV (phase 1), genital herpes (phase 1), genital warts and hepatitis B | DNA-based vaccine delivered by gene gun | DNA vaccines. Partnered with GlaxoSmithKline (HIV) |
| http://www.powdermed.com/ | |||
| Protein Sciences (Meriden, CT, USA) | Influenza (phase 3) and SARS | Recombinant subunit protein vaccine produced in baculovirus expression system | Antigen and protein reagents, vaccines R&D and contract manufacturing services. Contract with NIAID to produce SARS S-protein subunit vaccine |
| http://www.proteinsciences.com/ | |||
| Sciogen (San Francisco) | Influenza and SARS | Live viral vaccines attenuated by recombinant technology | Vaccines and biopharmaceuticals |
| http://www.sciogeninc.com/ |